Efficacy News and Research

RSS

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.

10 May 2013

Mathematical model with prognostic factors predicts treatment effect with bevacizumab in colorectal cancer patients

Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.

9 May 2013

More work needed to understand use of nanosilver, say researchers

Researchers from the University of New South Wales have cautioned that more work is needed to understand how micro-organisms respond to the disinfecting properties of silver nano-particles, increasingly used in medical and environmental applications.

9 May 2013

Antitumor medication from natural origins on the rise

Natural phenolic compounds play an important role in cancer prevention and treatment. Researchers who examine the medicinal herbs and dietary plants that can aid in cancer treatment and prevention have found that antitumor medication from natural origins is on the rise.

9 May 2013

TRACK-HD study: A set of tests could help identify progression of Huntington's disease

Scientists have identified a set of tests that could help identify whether and how Huntington's disease is progressing in groups of people who are not yet showing symptoms.

9 May 2013

FDA accepts Merck's BLA for investigational ragweed pollen sublingual allergy immunotherapy tablet

Merck, known as MSD outside the United States and Canada, today announced that the Biologics License Application for its investigational ragweed pollen (Ambrosia artemisiifolia) sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration.

9 May 2013

New technique can lead to effective use of nanoparticles as drug delivery system

A Wayne State University researcher has successfully tested a technique that can lead to more effective use of nanoparticles as a drug delivery system.

8 May 2013

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited.

8 May 2013

New VLP vaccine candidate produced for H7N9 virus

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is responsible for the current influenza outbreak in China.

8 May 2013

Cell Medica treats first pediatric patient in ASPIRE Trial

Cell Medica today announced the treatment of the first patient in the ASPIRE Trial, an early stage Phase I/II clinical study investigating the safety and efficacy of Cytovir ADV for the treatment of adenovirus infections in immunosuppressed pediatric patients following bone marrow transplantation.

8 May 2013

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries.

8 May 2013

Clinical data of cabozantinib to be presented at ASCO meeting

Exelixis, Inc. announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology.

8 May 2013

Isis begins clinical study of ISIS-STAT3 in patients with metastatic liver cancer

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1b/2a clinical study of ISIS-STAT3Rx in patients with advanced metastatic hepatocellular carcinoma (HCC).

7 May 2013

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.

7 May 2013

AUA and ASTRO release new guideline on adjuvant and salvage radiotherapy after prostatectomy

The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) are pleased to announce the publication of the joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence.

7 May 2013

New form of electroconvulsive therapy could prevent adverse cognitive side effects

Electroconvulsive therapy (ECT) is the most effective acute treatment for severe major depression. However, even with newer forms of ECT, there remains a significant risk of adverse cognitive effects, particularly memory problems.

7 May 2013

Pharmapendium adds new module to benefit researchers and toxicologists

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announces that PharmaPendium, the leading source of preclinical, clinical and post-market data, has added a new module to its content base, the Metabolizing Enzymes and Transporters Module.

6 May 2013

Oral drops provide a safe and effective alternative for allergy sufferers

Allergy shots are commonly used to treat children with severe environmental allergies and asthma, but under-the-tongue drops may offer yet another beneficial - and stick-free - option for pediatric allergy sufferers, according to a Johns Hopkins Children's Center review of existing scientific evidence.

6 May 2013

Researchers issue statement regarding use of unproven stem cell therapies

An international group of leading stem cell researchers has issued a statement that specifies concerns about the development and use of unproven stem cell therapies.

4 May 2013

Martindale Pharma announces UK launch of Prenoxad Injection for opioid overdose

Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Prenoxad Injection, the world's first licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings.

3 May 2013

Efficacy News and Research

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

Mathematical model with prognostic factors predicts treatment effect with bevacizumab in colorectal cancer patients

More work needed to understand use of nanosilver, say researchers

Antitumor medication from natural origins on the rise

TRACK-HD study: A set of tests could help identify progression of Huntington's disease

FDA accepts Merck's BLA for investigational ragweed pollen sublingual allergy immunotherapy tablet

New technique can lead to effective use of nanoparticles as drug delivery system

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

New VLP vaccine candidate produced for H7N9 virus

Cell Medica treats first pediatric patient in ASPIRE Trial

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Clinical data of cabozantinib to be presented at ASCO meeting

Isis begins clinical study of ISIS-STAT3 in patients with metastatic liver cancer

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

AUA and ASTRO release new guideline on adjuvant and salvage radiotherapy after prostatectomy

New form of electroconvulsive therapy could prevent adverse cognitive side effects

Pharmapendium adds new module to benefit researchers and toxicologists

Oral drops provide a safe and effective alternative for allergy sufferers

Researchers issue statement regarding use of unproven stem cell therapies

Martindale Pharma announces UK launch of Prenoxad Injection for opioid overdose

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News